Get started
Author

Sylvia Hafkemeyer

Observed names: S Hafkemeyer, S. Hafkemeyer
ORCID: 0000-0003-1221-9643
Observed ORCID: 0000-0003-1221-9643
OpenAlex ID: A5065077936
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
2024 · Andrea Gramegna, Charlotte Addy, et al. · Journal of Cystic Fibrosis · 50
PDF
Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis
2023 · Anna-Maria Dittrich, Sarah Sieber, et al. · International Journal of Infectious Diseases · 49
PDF
Molecular Epidemiology of Mycobacterium abscessus Isolates Recovered from German Cystic Fibrosis Patients
2022 · Nils Wetzstein, Margo Diricks, et al. · Microbiology Spectrum · 28
CFTR: New insights into structure and function and implications for modulation by small molecules
2019 · Bertrand Kleizen, John F. Hunt, et al. · Journal of Cystic Fibrosis · 22
PDF
Epidemiological trends in nontuberculous mycobacterial infection among people with cystic fibrosis in Germany
2023 · Mathis Steindor, Sylvia Hafkemeyer, et al. · International Journal of Infectious Diseases · 13
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
2021 · Claudia Grehn, A.-M. Dittrich, et al. · Journal of Cystic Fibrosis · 11
CFTR Lifecycle Map—A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations
2021 · Liza Vinhoven, Frauke Stanke, et al. · International Journal of Molecular Sciences · 9
PDF
Integrating Text Mining into the Curation of Disease Maps
2022 · Malte Voskamp, Liza Vinhoven, et al. · Biomolecules · 6
PDF
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany
2023 · S. Naehrig, B. Schulte-Hubbert, et al. · Pulmonary Pharmacology & Therapeutics · 5
Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis
2022 · Liza Vinhoven, Frauke Stanke, et al. · International Journal of Molecular Sciences · 3
PDF
Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR
2021 · Manuel Manfred Nietert, Liza Vinhoven, et al. · Frontiers in Pharmacology · 3
WS10.05 Reduction of pulmonary exacerbations in people with cystic fibrosis in Germany between 2019 and 2022
2023 · S. Naehrig, O. Eickmeier, et al. · Journal of Cystic Fibrosis · 1
PDF
A consensus-based guideline for personalized bacteriophage therapy
2026 · Silvia Würstle, Simone C. Lieberknecht-Jouy, et al. · Nature Medicine
PDF
Rethinking informed consent in phage therapy: why location and approach matter
2026 · Ran Nir-Paz, Jean-Paul Pirnay, et al. · Clinical Microbiology and Infection
Azithromycintherapie bei Menschen mit zystischer Fibrose: Real-World Evidence aus dem Deutschen Mukoviszidose-Register
2026 · Z Syunyaeva, S Hafkemeyer, et al. · Pneumologie
Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry
2025 · Mirjam Stahl, Florian S. Gerts, et al. · ERJ Open Research
114 Real-world evidence from the German cystic fibrosis registry on off- label treatment effects of elexacaftor/tezacaftor/ivacaftor
2025 · M. Stahl, F. Gerts, et al. · Journal of Cystic Fibrosis
599 Highly-effective CFTR modulator therapy with elexacaftor-tezacaftorivacaftor leads to age-dependent changes in cystic fibrosis microbiology—data from the German cystic fibrosis registry
2023 · A. Dittrich, S. Sieber, et al. · Journal of Cystic Fibrosis
PDF
Epidemiological Trends in Nontuberculous Mycobacterial Infection among People with Cystic Fibrosis in Germany
2023 · Mathis Steindor, Sylvia Hafkemeyer, et al. · European Respiratory Journal
WS16.01 Highly-effective CFTR modulator therapy with elexacaftor/tezacaftor/ivacftor (ETI) leads to age-dependent changes of typical cystic fibrosis hallmark pathogens – data from the German cystic fibrosis registry
2023 · A. Dittrich, S. Sieber, et al. · Journal of Cystic Fibrosis
PDF
Epidemiologische Trends bei Infektionen mit nichttuberkulösen Mykobakterien bei Patienten mit Mukoviszidose in Deutschland
2023 · Mathis Steindor, Sylvia Hafkemeyer, et al. · Klinische Pädiatrie
P025 Systems biology modelling of CFTR maturation to predict possible active compound combinations
2021 · L. Vinhoven, F. Stanke, et al. · Journal of Cystic Fibrosis
P027 Comprehensive analysis of chemical structures that have been tested as CFTR-activating substances in a public available database CandActCFTR
2019 · M.M. Nietert, L. Vinhoven, et al. · Journal of Cystic Fibrosis
Works count: 23
Citation count: 200
H-index: 7
I10-index: 6
Year
Topic
Type